Mirdametinib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. Upon administration, mirdametinib selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.

**Synonyms:** - Gomekli - MEK Inhibitor PD0325901 - MIRDAMETINIB - PD 901 - PD-0325901